^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NCAM1 positive

    i
    Other names: NCAM1, CD56, NCAM, Neural cell adhesion molecule 1
    Entrez ID:
    4684
    Related biomarkers:
    Expression
    21d
    Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 positive
    |
    Erleada (apalutamide)
    1m
    Desmoplastic Small Round Cell Tumor in a Young Adult: A Case Report Highlighting Diagnostic Challenges and Treatment Approaches. (PubMed, Cureus)
    The patient was placed on a regimen alternating the combination of vincristine, doxorubicin, and cyclophosphamide for one week and ifosfamide and etoposide for the next. It also discusses the complexity and challenges of managing this rare aggressive malignancy. This case report also addresses the necessity for advanced research into targeted therapies and optimized strategies in the treatment to help improve the survival rates and quality of life for patients with DSRCT.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 positive
    |
    doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine
    2ms
    Evaluation of CD56 and CD117 Double-positive as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis. (PubMed, Turk J Haematol)
    The high cytogenetic risk was found to bean independent predictor of shorter OS (p>0.001). The study's findings revealed that CD56 and CD117 double- positive MM patients had poorer prognosis, lower ORR, shorter OS, and higher mortality.
    Retrospective data • Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • NCAM1 (Neural cell adhesion molecule 1)
    |
    KIT expression • NCAM1 positive
    6ms
    The RTK-RAS signaling pathway is enriched in patients with rare acute myeloid leukemia harboring t(16;21)(p11;q22)/FUS::ERG. (PubMed, Blood Sci)
    Transcriptome analysis revealed enrichment of the phosphatidylinositol-3-kinase-Akt (PI3K-Akt), mitogen-activated protein kinase (MAPK), and RAS signaling pathways and upregulation of BCL2, the target of venetoclax, in FUS::ERG AML compared to RUNX1::RUNX1T1 AML, a more common AML subtype with good prognosis...Allogeneic hematopoietic stem cell transplantation failed to improve outcomes. Overall, the high incidence of RTK-RAS pathway mutations and high expression of BCL2 may indicate promising therapeutic targets in this high-risk AML subset.
    Journal • IO biomarker
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • RUNX1 (RUNX Family Transcription Factor 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • NCAM1 (Neural cell adhesion molecule 1) • FUS (FUS RNA Binding Protein)
    |
    KRAS mutation • RAS mutation • BCL2 overexpression • BCL2 expression • NCAM1 positive
    |
    Venclexta (venetoclax)
    7ms
    Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2024 --> Jan 2027 | Trial primary completion date: Aug 2024 --> Jan 2025
    Trial completion date • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 positive
    |
    Erleada (apalutamide)
    7ms
    Immunoglobulin-like transcript 2 as an impaired anti-tumor cytotoxicity marker of natural killer cells in patients with hepatocellular carcinoma. (PubMed, Front Immunol)
    In HCC patients, ILT2 is a signature molecule for cancerous CD56dim NK cells with impaired cytolytic capacity. The MIF-CXCR4 interaction is associated with ILT2 induction on CD56dim NK cells and ILT2 serves as a target for functional NK cell restoration.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • MIF (Macrophage Migration Inhibitory Factor)
    |
    NCAM1 positive
    8ms
    A Case of Relapsed/Refractory CD56-Positive Acute Promyelocytic Leukemia, in Which Complete Molecular Remission Was Achieved Following Combination Therapy with Venetoclax and Azacitidine. (PubMed, Gan To Kagaku Ryoho)
    In August Year X-1, she developed molecular relapse and was started on tamibarotene(Am80). She died of gastrointestinal hemorrhage. This is considered a valuable case for accumulating information on the treatment of CD56-positive APL resistant to ATRA and ATO.
    Journal • Combination therapy
    |
    RARA (Retinoic Acid Receptor Alpha) • NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 positive
    |
    Venclexta (venetoclax) • azacitidine • Amnolake (tamibarotene)
    11ms
    Expression and Clinical Significance of CD30 and CD56 in Lymphoblastic Lymphoma: A Retrospective Analysis on Paraffin-Embedded Tissues by Immunohistochemistry. (PubMed, Fetal Pediatr Pathol)
    CD56 is a potential negative prognostic marker. These findings suggest that CD30 and CD56 targeted therapies could be potential therapeutic targets for LBL patients.
    Retrospective data • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • NCAM1 (Neural cell adhesion molecule 1)
    |
    TNFRSF8 expression • NCAM1 expression • NCAM1 positive
    12ms
    Diagnostic Challenges in the Leukemia Phase of Blastic Plasmacytoid Dendritic Cell Neoplasm without Skin Involvement: A Clinical and Pathological Study (ASH 2023)
    Only one cycle of decitabine + CAG was given and 5 months later, the disease progressed to the leukemia phase...The latter case had ASXL1 and TET2 mutations detected by NGS analysis, achieved complete remission after receiving venetoclax + azacitidine for one cycle, followed by intermittent venoclax +demethylation agent or low-dose chemotherapy maintenance treatment and live for more than two years now... BPDCN without skin lesions is clinically rare, and its diagnosis is challenging. Comprehensive immunophenotyping and cautious interpretation of immunohistochemistry results such as dim lysozyme expression are crucial. Venetoclax-containing regimens have shown promising therapeutic effects.
    Clinical
    |
    TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • CD36 (thrombospondin receptor) • NCAM1 (Neural cell adhesion molecule 1) • CD5 (CD5 Molecule) • CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • NRP1 (Neuropilin 1) • SPN (Sialophorin) • TCL1A (TCL1 Family AKT Coactivator A) • ANPEP (Alanyl Aminopeptidase, Membrane) • CLEC4C (C-Type Lectin Domain Family 4 Member C) • MPO (Myeloperoxidase)
    |
    TP53 mutation • ASXL1 mutation • TET2 mutation • CD123 positive • NCAM1 expression • CD123 expression • CD4 expression • IDH2 mutation + TP53 mutation • IL3RA positive • NCAM1 positive
    |
    Venclexta (venetoclax) • azacitidine • decitabine
    12ms
    Clonal Bone Marrow Plasma Cells Are Common in Patients with Vexas Syndrome (ASH 2023)
    Cytoplasmic cyclin D1 expression may be related to lack of cyclin D1 protein degradation by a defective UBA1 gene product. Our results suggest that defective UBA1 and autoinflammation pose an increased risk for developing MGUS or multiple myeloma.
    Clinical • IO biomarker
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule) • IRF4 (Interferon regulatory factor 4) • CD81 (CD81 Molecule)
    |
    CD20 positive • CD20 expression • CD19 expression • CCND1 expression • SDC1 positive • NCAM1 positive
    12ms
    Prognostic implications of synaptophysin, CD56, thyroid transcription factor-1, and Ki-67 in pulmonary high-grade neuroendocrine carcinomas. (PubMed, Ann Diagn Pathol)
    Positive expression of Syn was associated with reduced PFS and OS, while positive CD56 expression was correlated with a shorter OS in HGNEC. The TNM stage was an independent risk factor that significantly influenced PFS and OS in patients with HGNEC. More studies are needed to make further progress in future treatment.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • NKX2-1 (NK2 Homeobox 1) • SYP (Synaptophysin)
    |
    NCAM1 expression • NCAM1 positive
    1year
    Survival benefit and biomarker of PD-1 inhibitor combination therapy in first-line of advanced biliary tract cancer: A retrospective study. (PubMed, Cancer Med)
    First-line anti-PD-1 combination therapy was superior to chemotherapy, and triple therapy significantly improved survival. Peripheral blood immune-inflammation score, FOXP3/CD8 ratio, and PLUS have potential as biomarkers for predicting the efficacy of first-line anti-PD-1 therapy in advanced BTC.
    Retrospective data • Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • FOXP3 (Forkhead Box P3)
    |
    TP53 mutation • KRAS mutation • HER-2 mutation • CD8-H • NCAM1 positive
    1year
    Proteomic Analysis of Monoclonal Plasma Cells from Plasma Cell Dyscrasias (ASH 2023)
    Comparison of pre- and post-treatment samples showed distinct protein expression patterns according to therapeutic agents (daratumumab and carfilzomib). The current results may contribute to the understanding of differences between each plasma cell dyscrasias and mechanisms of resistance to therapeutic agents.
    IO biomarker • Omic analysis
    |
    NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • SLAMF7 (SLAM Family Member 7)
    |
    CD38 expression • NCAM1 positive
    |
    Darzalex (daratumumab) • carfilzomib
    1year
    Clonal Bone Marrow Plasma Cells Are Common in Patients with Vexas Syndrome (ASH 2023)
    Cytoplasmic cyclin D1 expression may be related to lack of cyclin D1 protein degradation by a defective UBA1 gene product. Our results suggest that defective UBA1 and autoinflammation pose an increased risk for developing MGUS or multiple myeloma.
    Clinical • IO biomarker
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule) • IRF4 (Interferon regulatory factor 4) • CD81 (CD81 Molecule)
    |
    CD20 positive • CD20 expression • CD19 expression • CCND1 expression • SDC1 positive • NCAM1 positive
    1year
    Human ILC1s Target Leukemia Stem Cells and Control Development of AML (ASH 2023)
    The use of UCB CD34+ HSCs to generate ILC1s, especially after being engineered with a CAR, could allow for a readily available supply of ILC1s to be produced for human adoptive transfer studies. Our findings provide evidence that targeting human ILC1s may be a promising therapeutic approach for extending disease-free survival in patients with AML.
    IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD38 (CD38 Molecule) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CD14 (CD14 Molecule) • CSF2 (Colony stimulating factor 2) • ITGAM (Integrin, alpha M) • MRC1 (Mannose Receptor C-Type 1) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)
    |
    CSF2 expression • NCAM1 positive
    1year
    Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial (ASH 2023)
    CIML NK cells were manufactured with a 100% success rate and infused at a target dose of 5-10x106 cells/kg-body weight, 24 hours after 200 mg/m2 melphalan administration. Regulatory T cells increased by D+7 (3% vs 15% total PBMC) and returned to baseline after D+14 most likely reflecting the effect of IL-2 treatment. The functional capacity of the infused product was tested in vitro
    Clinical • P1 data • IO biomarker
    |
    NCAM1 (Neural cell adhesion molecule 1) • IL18 (Interleukin 18) • IL15 (Interleukin 15) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1) • KLRC1 (Killer Cell Lectin Like Receptor C1)
    |
    NCAM1 positive
    |
    melphalan • BHV-1100 • CIML NK
    1year
    Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies (ASH 2023)
    In conclusion, our data suggest CD56 levels as an important determinant of sensitivity to DARA-based therapies. Moreover, our results suggest the next-generation NAMPT inhibitors as an additional therapeutic strategy for CD56-expressing MM patients.
    Clinical • IO biomarker
    |
    CD38 (CD38 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • NAMPT (Nicotinamide Phosphoribosyltransferase)
    |
    CD38 expression • NCAM1 expression • CD5 overexpression • NCAM1 overexpression • NCAM1 positive
    |
    Darzalex (daratumumab)
    1year
    Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies (clinicaltrials.gov)
    P1, N=33, Completed, Sumithira Vasu | Active, not recruiting --> Completed | Phase classification: PN/A --> P1
    Trial completion • Phase classification
    |
    CD8 (cluster of differentiation 8) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    NCAM1 positive
    |
    cyclophosphamide • methotrexate IV
    1year
    Palisading Adenocarcinoma: A Morphologically Unique Salivary Gland Tumor With a Neuroendocrine-like Appearance and a Predilection for the Sublingual Glands of Women. (PubMed, Am J Surg Pathol)
    Although a subset showed unequivocally invasive growth, this tumor appears to behave in an indolent manner. Moving forward, recognition of palisading adenocarcinoma and its separation from other salivary adenocarcinomas, NOS will facilitate a better understanding of the characteristics of this previously unrecognized tumor.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • SYP (Synaptophysin)
    |
    NCAM1 positive
    1year
    Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia. (PubMed, Cell Transplant)
    Historically, at our center, patients with refractory AML have been treated with cytoreductive therapy (fludarabine + cytosine + granulocyte colony-stimulating factor ± idarubicin or mitoxantrone + etoposide) followed by 1-week rest and then reduced-intensity transplant with fludarabine + melphalan...CD56-positive selection was done using a CliniMACS Prodigy system (Miltenyi Biotec, Bergisch Gladbach, Germany) followed by overnight incubation in autologous plasma with 2 micromolar arsenic trioxide and 500 U/mL of interleukin-2...Haploidentical NK cell therapy as an adjunct to transplant is safe and needs further exploration in patients with AML. For refractory AML, post-transplant NK infusion and strategies to reduce TRM while using pre-transplant NK infusion merit exploration.
    Journal
    |
    IL2 (Interleukin 2) • NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 positive
    |
    etoposide IV • idarubicin hydrochloride • mitoxantrone • melphalan • arsenic trioxide • fludarabine IV
    over1year
    PIONEER: Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN (clinicaltrials.gov)
    P2, N=20, Recruiting, University Hospital, Essen | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
    Trial completion date • Trial primary completion date
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • EPCAM (Epithelial cell adhesion molecule) • VIM (Vimentin) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CEACAM8 (CEA Cell Adhesion Molecule 8)
    |
    NCAM1 positive
    |
    Tecentriq (atezolizumab)